Drug intelligence / Profile preview

PRO-143

Development stage: Discontinued
Lead developer: Lantheus
Administration: Ophthalmic

Overview

PRO-143 is an investigational ophthalmic solution that has been evaluated in clinical studies for safety and tolerability in healthy volunteers. The specific mechanism of action, molecular target, and therapeutic indication are not publicly disclosed. Available information indicates it is being developed as an eye drop formulation, but no further details on its pharmacological class or intended disease area have been published[3].

Beyond the preview

Go deeper on PRO-143.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO-143.

Explore the full profile